UPB
Upstream Bio, Inc.
-0.01 (-0.19%)5.32USD124K成交股數291M市值–本益比(近四季)92.3股價營收比-17.5%營收年增(近四季)2026-11-04下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
| 其中 10b5-1 計畫賣出 | 0 筆 |
| 近 180 天 買進 · 賣出金額 | 0.00 · 31K |
| 近 180 天 淨額 | −31K |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-16 | 06-17 | Ambrose Allison | General Counsel | S 公開市場賣出 | 477 | 6.10 | 3K | 16.0K | SEC |
| 2026-06-16 | 06-17 | Deykin Aaron | Chief Medical Officer | S 公開市場賣出 | 895 | 6.10 | 5K | 33.2K | SEC |
| 2026-06-16 | 06-17 | Houghton Adam | Chief Business Officer | S 公開市場賣出 | 700 | 6.10 | 4K | 23.6K | SEC |
| 2026-06-16 | 06-17 | Sutherland Everett Rand | Chief Executive Officer | S 公開市場賣出 | 2.1K | 6.10 | 13K | 70.8K | SEC |
| 2026-06-16 | 06-17 | GRAY MICHAEL | CFO and COO | S 公開市場賣出 | 853 | 6.10 | 5K | 28.8K | SEC |
| 2026-03-16 | 03-17 | Houghton Adam | Chief Business Officer | S 公開市場賣出 | 699 | 9.29 | 6K | 24.3K | SEC |
| 2026-03-16 | 03-17 | Ambrose Allison | General Counsel | S 公開市場賣出 | 475 | 9.29 | 4K | 16.5K | SEC |
| 2026-03-16 | 03-17 | Sutherland Everett Rand | Chief Executive Officer | S 公開市場賣出 | 2.1K | 9.29 | 19K | 72.9K | SEC |
| 2026-03-16 | 03-17 | Deykin Aaron | Chief Medical Officer | S 公開市場賣出 | 894 | 9.29 | 8K | 32.7K | SEC |
| 2026-03-16 | 03-17 | GRAY MICHAEL | CFO and COO | S 公開市場賣出 | 852 | 9.29 | 8K | 29.6K | SEC |
| 2026-01-02 | 01-06 | Sutherland Everett Rand | Chief Executive Officer | A 獲配股票 | 75.0K | – | – | 75.0K | SEC |
| 2026-01-02 | 01-06 | Houghton Adam | Chief Business Officer | A 獲配股票 | 25.0K | – | – | 25.0K | SEC |
| 2026-01-02 | 01-06 | Ambrose Allison | General Counsel | A 獲配股票 | 17.0K | – | – | 17.0K | SEC |
| 2026-01-02 | 01-06 | Deykin Aaron | Chief Medical Officer | A 獲配股票 | 32.0K | – | – | 33.6K | SEC |
| 2026-01-02 | 01-06 | GRAY MICHAEL | CFO and COO | A 獲配股票 | 30.5K | – | – | 30.5K | SEC |
| 2024-10-15 | 10-17 | ORBIMED ADVISORS LLC | Director,TenPercentOwner | C 轉換 | 722K | – | – | 974K | SEC |
| 2024-10-15 | 10-17 | ORBIMED ADVISORS LLC | Director,TenPercentOwner | P 公開市場買進 | 165K | 17.00 | 2.8M | 1.1M | SEC |
| 2024-10-15 | 10-17 | ORBIMED ADVISORS LLC | Director,TenPercentOwner | C 轉換 | 2.9M | – | – | 3.9M | SEC |
| 2024-10-15 | 10-17 | ORBIMED ADVISORS LLC | Director,TenPercentOwner | P 公開市場買進 | 660K | 17.00 | 11.2M | 4.6M | SEC |
| 2024-10-15 | 10-17 | OrbiMed Israel GP II, L.P. | Director,TenPercentOwner | C 轉換 | 722K | – | – | 974K | SEC |
| 2024-10-15 | 10-17 | OrbiMed Israel GP II, L.P. | Director,TenPercentOwner | P 公開市場買進 | 165K | 17.00 | 2.8M | 1.1M | SEC |
| 2024-10-15 | 10-17 | OrbiMed Israel GP II, L.P. | Director,TenPercentOwner | C 轉換 | 2.9M | – | – | 3.9M | SEC |
| 2024-10-15 | 10-17 | OrbiMed Israel GP II, L.P. | Director,TenPercentOwner | P 公開市場買進 | 660K | 17.00 | 11.2M | 4.6M | SEC |
| 2024-10-15 | 10-17 | OrbiMed Advisors Israel II Ltd | Director,TenPercentOwner | C 轉換 | 722K | – | – | 974K | SEC |
| 2024-10-15 | 10-17 | OrbiMed Advisors Israel II Ltd | Director,TenPercentOwner | P 公開市場買進 | 165K | 17.00 | 2.8M | 1.1M | SEC |
| 2024-10-15 | 10-17 | OrbiMed Advisors Israel II Ltd | Director,TenPercentOwner | C 轉換 | 2.9M | – | – | 3.9M | SEC |
| 2024-10-15 | 10-17 | OrbiMed Advisors Israel II Ltd | Director,TenPercentOwner | P 公開市場買進 | 660K | 17.00 | 11.2M | 4.6M | SEC |
| 2024-10-15 | 10-17 | OrbiMed Capital GP VIII LLC | Director,TenPercentOwner | C 轉換 | 722K | – | – | 974K | SEC |
| 2024-10-15 | 10-17 | OrbiMed Capital GP VIII LLC | Director,TenPercentOwner | P 公開市場買進 | 165K | 17.00 | 2.8M | 1.1M | SEC |
| 2024-10-15 | 10-17 | OrbiMed Capital GP VIII LLC | Director,TenPercentOwner | C 轉換 | 2.9M | – | – | 3.9M | SEC |
| 2024-10-15 | 10-17 | OrbiMed Capital GP VIII LLC | Director,TenPercentOwner | P 公開市場買進 | 660K | 17.00 | 11.2M | 4.6M | SEC |
| 2024-10-15 | 10-17 | Chimovits Erez | Director,TenPercentOwner | C 轉換 | 722K | – | – | 974K | SEC |
| 2024-10-15 | 10-17 | Chimovits Erez | Director,TenPercentOwner | P 公開市場買進 | 165K | 17.00 | 2.8M | 1.1M | SEC |
| 2024-10-15 | 10-17 | Chimovits Erez | Director,TenPercentOwner | C 轉換 | 2.9M | – | – | 3.9M | SEC |
| 2024-10-15 | 10-17 | Chimovits Erez | Director,TenPercentOwner | P 公開市場買進 | 660K | 17.00 | 11.2M | 4.6M | SEC |
| 2024-10-15 | 10-17 | Blavatnik Len | TenPercentOwner | P 公開市場買進 | 1.2M | 17.00 | 20.0M | 1.2M | SEC |
| 2024-10-15 | 10-17 | Blavatnik Len | TenPercentOwner | C 轉換 | 3.1M | – | – | 4.3M | SEC |
| 2024-10-15 | 10-17 | Blavatnik Len | TenPercentOwner | C 轉換 | 1.2M | – | – | 5.5M | SEC |
| 2024-10-15 | 10-17 | Access Industries Holdings LLC | TenPercentOwner | P 公開市場買進 | 1.2M | 17.00 | 20.0M | 1.2M | SEC |
| 2024-10-15 | 10-17 | Access Industries Holdings LLC | TenPercentOwner | C 轉換 | 3.1M | – | – | 4.3M | SEC |
| 2024-10-15 | 10-17 | Access Industries Holdings LLC | TenPercentOwner | C 轉換 | 1.2M | – | – | 5.5M | SEC |
| 2024-10-15 | 10-17 | ACCESS INDUSTRIES MANAGEMENT, LLC | TenPercentOwner | P 公開市場買進 | 1.2M | 17.00 | 20.0M | 1.2M | SEC |
| 2024-10-15 | 10-17 | ACCESS INDUSTRIES MANAGEMENT, LLC | TenPercentOwner | C 轉換 | 3.1M | – | – | 4.3M | SEC |
| 2024-10-15 | 10-17 | ACCESS INDUSTRIES MANAGEMENT, LLC | TenPercentOwner | C 轉換 | 1.2M | – | – | 5.5M | SEC |
| 2024-10-15 | 10-17 | AI Biotechnology LLC | TenPercentOwner | P 公開市場買進 | 1.2M | 17.00 | 20.0M | 1.2M | SEC |
| 2024-10-15 | 10-17 | AI Biotechnology LLC | TenPercentOwner | C 轉換 | 3.1M | – | – | 4.3M | SEC |
| 2024-10-15 | 10-17 | AI Biotechnology LLC | TenPercentOwner | C 轉換 | 1.2M | – | – | 5.5M | SEC |
| 2024-10-15 | 10-17 | AI Upstream LLC | TenPercentOwner | P 公開市場買進 | 1.2M | 17.00 | 20.0M | 1.2M | SEC |
| 2024-10-15 | 10-17 | AI Upstream LLC | TenPercentOwner | C 轉換 | 3.1M | – | – | 4.3M | SEC |
| 2024-10-15 | 10-17 | AI Upstream LLC | TenPercentOwner | C 轉換 | 1.2M | – | – | 5.5M | SEC |
| 2024-10-15 | 10-15 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | TenPercentOwner | C 轉換 | 895K | – | – | 895K | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| FMR LLC | 8.2M | 56.5M | 新進 | 新進 |
| ORBIMED ADVISORS LLC | 5.7M | 39.4M | 新進 | 新進 |
| 挪威主權基金 NORGES BANK | 3.8M | 26.1M | 新進 | 新進 |
| BlackRock, Inc. | 3.8M | 26.0M | 新進 | 新進 |
| Decheng Capital LLC | 2.7M | 18.9M | 新進 | 新進 |
| ENAVATE SCIENCES GP, LLC | 2.5M | 17.0M | 新進 | 新進 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.9M | 13.0M | 新進 | 新進 |
| 千禧 MILLENNIUM MANAGEMENT LLC | 1.1M | 7.9M | 新進 | 新進 |
| 德劭 D. E. Shaw & Co., Inc. | 1.0M | 7.2M | 新進 | 新進 |
| JPMORGAN CHASE & CO | 1.0M | 7.0M | 新進 | 新進 |
| Qube Research & Technologies Ltd | 979K | 6.8M | 新進 | 新進 |
| Parkman Healthcare Partners LLC | 935K | 6.5M | 新進 | 新進 |
| GEODE CAPITAL MANAGEMENT, LLC | 931K | 6.4M | 新進 | 新進 |
| SEB Asset Management AB | 878K | 6.1M | 新進 | 新進 |
| Woodline Partners LP | 831K | 5.8M | 新進 | 新進 |
| STATE STREET CORP | 766K | 5.3M | 新進 | 新進 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 713K | 4.9M | 新進 | 新進 |
| Y-Intercept (Hong Kong) Ltd | 694K | 4.8M | 新進 | 新進 |
| Bain Capital Life Sciences Investors, LLC | 601K | 4.2M | 新進 | 新進 |
| AQR CAPITAL MANAGEMENT LLC | 545K | 3.8M | 新進 | 新進 |
| MORGAN STANLEY | 525K | 3.6M | 新進 | 新進 |
| BNP PARIBAS FINANCIAL MARKETS | 512K | 3.5M | 新進 | 新進 |
| Walleye Capital LLC | 498K | 3.4M | 新進 | 新進 |
| Trexquant Investment LP | 466K | 3.2M | 新進 | 新進 |
| Point72(柯恩) Point72 Asset Management, L.P. | 453K | 3.1M | 新進 | 新進 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 149 +8 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 149 / 0 / 0 / 0 |
| 機構合計持股 · 佔流通股 | 50.6M · 92.3% |
| 合計季末市值 | 347M |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 4.1M |
|---|---|
| 與上期比 | +1.9% |
| 佔流通股數 | 7.48% |
| 日均成交量 | 550K |
| 回補天數 | 7.5 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 4.1M | +1.9% | 7.48% | 550K | 7.5 |
| 2026-08-14 | 4.0M | +10.1% | 7.33% | 712K | 5.6 |
| 2026-07-31 | 3.6M | +0.8% | 6.66% | 487K | 7.5 |
| 2026-07-15 | 3.6M | -11.9% | 6.61% | 442K | 8.2 |
| 2026-06-30 | 4.1M | +5.3% | 7.50% | 718K | 5.7 |
| 2026-06-15 | 3.9M | +7.1% | 7.12% | 711K | 5.5 |
| 2026-05-29 | 3.6M | +7.2% | 6.65% | 534K | 6.8 |
| 2026-05-15 | 3.4M | +5.4% | 6.20% | 508K | 6.7 |
| 2026-04-30 | 3.2M | +6.6% | 5.89% | 564K | 5.7 |
| 2026-04-15 | 3.0M | -12.0% | 5.52% | 577K | 5.2 |
| 2026-03-31 | 3.4M | -27.7% | 6.27% | 992K | 3.5 |
| 2026-03-13 | 4.8M | +16.3% | 8.68% | 1.1M | 4.4 |
| 2026-02-27 | 4.1M | +15.8% | 7.46% | 2.2M | 1.8 |
| 2026-02-13 | 3.5M | +10.9% | 6.44% | 2.3M | 1.5 |
| 2026-01-30 | 3.2M | -7.8% | 5.81% | 574K | 5.5 |
| 2026-01-15 | 3.5M | -1.0% | 6.30% | 652K | 5.3 |
| 2025-12-31 | 3.5M | +16.9% | 6.37% | 606K | 5.8 |
| 2025-12-15 | 3.0M | +7.6% | 5.45% | 534K | 5.6 |
| 2025-11-28 | 2.8M | -7.4% | 5.06% | 541K | 5.1 |
| 2025-11-14 | 3.0M | +2.2% | 5.47% | 383K | 7.8 |
| 2025-10-31 | 2.9M | -12.2% | 5.35% | 372K | 7.9 |
| 2025-10-15 | 3.3M | -6.4% | 6.09% | 325K | 10.3 |
| 2025-09-30 | 3.6M | +18.4% | 6.51% | 554K | 6.4 |
| 2025-09-15 | 3.0M | -2.8% | 5.50% | 663K | 4.5 |
| 2025-08-29 | 3.1M | -2.0% | 5.66% | 353K | 8.8 |
| 2025-08-15 | 3.2M | +2.6% | 5.77% | 491K | 6.4 |